Submit Science – Scientific Sessions 2024

We want your science at #AHA24!

You want to be noticed for your great science, and Scientific Sessions 2024 is the place to showcase your work. 

Wondering why you should submit?

2024 Abstract Categories

Basic Science
Arteriosclerosis, Thrombosis and Vascular Biology
No. Category Council
1.01 Lipids, Lipid Mediators, and Lipoprotein Metabolism: Cellular and Animal ATVB
1.02 Angiogenesis, Vascular Development and Regeneration ATVB
1.03 Atherosclerosis, Hemostasis and Thrombosis and Fibrinolysis ATVB
1.04 Endothelium, Vascular Tone and Nitric Oxide ATVB
1.05 Differentiation, Remodeling, Extracellular Matrix ATVB
1.06 Stem/Progenitor Cells ATVB
1.07 Microcirculation and Cerebral/Coronary/Peripheral Circulation ATVB
1.08 Inflammation and Adhesion Molecules ATVB


Cardiac Development, Structure and Function
No. Category Council
2.09 Cardiac Development BCVS
2.10 Protection of Ischemic Myocardium and Myocardial Repair BCVS
2.11 Cardiac Hypertrophy, Heart Failure and Ventricular Remodeling BCVS


Genetics and Genomics
No. Category Council
3.12 Gene Expression/Molecular Biology BCVS
3.13 Functional Genomics, Transcriptomics, Proteomics and Metabolomics of Cardiovascular Disease GPM
3.14 Genetic Epidemiology, Genomics, Gene-Based Therapies, Gene Editing and Pharmacogenomics GPM
3.15 Precision Medicine- Genetic and Genomic Applications GPM


Molecular and Cellular Science
No. Activity Council
4.16 Cellular Signaling BCVS
4.17 Drug Discovery for Cardiovascular Disease BCVS
4.18 Cardiac Metabolism and Energetics BCVS
4.19 Cardiorenal Physiology/Pathophysiology KCVD
4.20 Ischemic Myocardium ATVB
4.21 Electrophysiology and Experimental Models of Arrhythmias BCVS
4.22 Cell and Tissue Engineering GPM

Clinical Science
Acute Coronary Syndromes
No. Category Council
5.23 Unstable Angina, NSTEMI and STEMI: Diagnosis and Pathophysiology CLCD
5.24 Unstable Angina, NSTEMI and STEMI: Prognosis and Pharmacologic Therapy CLCD
5.25 Chronic Coronary Disease CLCD
5.26 Clinical Biomarkers in ACS CLCD


Brain Health and Cerebrovascular Science
No. Category Council
6.27 Cerebrovascular Diseases/Stroke (Basic, Clinical & Population) Stroke
6.28 Brain Health Stroke


Cardio-Oncology
No. Category Council
7.29 Cardio-Oncology CLCD


Congenital Heart Disease and Pediatric Cardiology
No. Category Council
8.30 Pediatric Congenital Heart Defects Young Hearts
8.31 Pediatric Acquired Heart Disease (i.e. infectious diseases, other) Young Hearts
8.32 Pediatric Imaging Young Hearts
8.33 Pediatric Electrophysiology Young Hearts
8.34 Pediatric Epidemiology and Population Prevention Young Hearts
8.35 Pediatric Clinical Preventive Cardiovascular Disease Young Hearts
8.36 Pediatric Cardiac Surgery Young Hearts
8.37 Adult Congenital Heart Disease Young Hearts
8.38 Pediatric Heart Failure/Transplantation Young Hearts
8.39 Pediatric Critical Care Cardiology Young Hearts


Electrophysiology and Arrhythmias
No. Category Council
9.40 Arrhythmia: Clinical Electrophysiology Diagnosis CLCD
9.41 Arrhythmia: Clinical Electrophysiology Risk Stratification CLCD
9.42 Treatment of Arrhythmias: Pharmacologic CLCD
9:43 Treatment of Arrhythmias: Ablation and Surgery CLCD
9.44 Treatment of Arrhythmias: Device Therapy CLCD


Heart Failure and Cardiomyopathies
No. Category Council
10.45 Heart Failure and Cardiomyopathies: Diagnosis & Evaluation CLCD
10.46 Heart Failure and Cardiomyopathies: Pathophysiology BCVS
10.47 Heart Failure and Cardiomyopathies: Pharmacologic Therapy CLCD
10.48 Heart Failure and Cardiomyopathies: Pacing and Other Therapeutic Devices CLCD
10.49 Heart Failure and Cardiomyopathies: Disease Management CLCD
10.50 Heart Failure and Cardiomyopathies: Quality of Care, and Clinical Outcomes CLCD
10.51 End Stage Heart Failure: Transplantation (Medical) and Medical Therapy CLCD
10.52 Palliative and End of Life Care CLCD


Hypertension
No. Category Council
11.53 Hypertension: Basic and Translational HTN
11.54 Hypertension: Clinical HTN


Interventional Treatments
No. Category Council
12.55 Pharmacology for PCI CLCD
12.56 Catheter-Based Coronary Interventions CLCD
12.57 Endovascular Therapy PVD
12.58 Percutaneous Non-Coronary Cardiac Intervention (including Percutaneous Valves) CLCD
12.59 Catheter-Based Coronary Imaging and Hemodynamics CLCD


Multimodality Imaging
No. Category Council
13.60 Echocardiography: Evaluation of Systolic and Diastolic Function CLCD
13.61 Echocardiography: Emerging/New Technologies CLCD
13.62 Echocardiography in Clinical Syndromes CLCD
13.63 Nuclear Cardiology CLCD
13.64 Computed Tomography (CT): Heart CVRI
13.65 Magnetic Resonance Imaging (MRI): Heart CVRI
13.66 Non-Coronary Vascular Imaging (CT/MRI/Other) CVRI


Nephrology
No. Category Council(s)
14.67 Nephrology KCVD


Nursing Research and Clinical Science
No. Category Council
15.68 Primary Care, Prevention, Education, and Disease Management CVSN
15.69 Psychosocial and Behavioral Aspects CVSN
15.70 Acute and Chronic Care CVSN


Pulmonary Hypertension and Critical Care
No. Category Council
16.71 Pulmonary Hypertension and Diseases Involving Pulmonary Circulation 3CPR
16.72 Critical Care Cardiology 3CPR
16.73 Right Venticular Function and Physiology 3CPR


Surgery & Anesthesia
No. Category Council
17.74 Thoracic Aortic Disease CVSA
17.75 Coronary Disease CVSA
17.76 Peri-operative Care CVSA
17.77 Valvular Heart Disease CVSA
17.78 Heart Failure, and Transplantation CVSA


Vascular Medicine
No. Category Council
18.79 Vascular Medicine: Clinical Science PVD
18.80 Vascular Medicine: Basic and Translational PVD
18.81 Vascular Medicine: Venous and Thromboembolic Disease PVD
Population Science
Cardiometabolic Health and Diabetes
No. Category Council
19.82 Obesity and Weight Management in CVD Risk and Prevention Lifestyle
19.83 Diabetes Mellitus and CVD: Prevention and Management Lifestyle
19.84 Cardiovascular Kidney and Metabolic Health Lifestyle




Epidemiology, Big Data and Precision Medicine
No. Category Council
20.85 Biomarkers, Risk Assessment and Risk Prediction EPI
20.86 Population-Based and Observational Studies EPI
20.87 Clinical and Hospital-Based Observational Studies EPI
20.88 Social Determinants of Health QCOR
20.89 Health Equity and Structural Racism EPI
20.90 Methodology and Data Science EPI


Go Red for Women and Underrepresented Populations
No. Category Council
21.91 Women's Health and Sex Differences CLCD
21.92 Aging and Care of the Older Adult CLCD
21.93 Health Disparities and Underrepresented Populations CLCD
21.94 Cardio-Obstetrics CLCD
21.95 LGBTQ+ Health CLCD


Health Tech
No. Category Council
22.96 Health Tech, Artificial Intelligence, and Machine Learning QCOR


Implementation Science
No. Category Council
23.97 Implementation Science EPI


Prevention and Lifestyle Medicine
No. Category Council
24.98 Nutrition in CVD Risk and Prevention Lifestyle
24.99 Exercise, Physical Activity and Rehabilitation Lifestyle
24.100 Workplace, Environmental and Culture of Health Lifestyle
24.101 Substance Use and CVD Lifestyle
24.102 Sleep Health Lifestyle
24.103 Stress Testing Exercise and Pharmacologic (includes Sports Cardiology) CLCD
24.104 Clinical Lipidology Lifestyle


Psychological Health and Wellbeing
No. Category Council
25.105 Psychological Health and WellBeing Stroke


Quality of Care and Outcomes Research
No. Category Council
26.106 Cardiovascular Health Policy QCOR
26.107 Quality of Care and Outcomes Research QCOR
26.108 Clinical Trial Design and Research Methodology QCOR
26.106 Disparities in Health Care Delivery QCOR
Broad Focus
Clinical Cases
No. Category
27.110 Clinical Case: Cardio-Oncology
27.111 Clinical Case: Congenital Heart Disease
27.112 Clinical Case: Critical Care Cardiology
27.113 Clinical Case: Electrophysiology and Arrhythmias
27.114 Clinical Case: Heart Failure and Cardiomyopathies
27.115 Clinical Case: Interventional Cardiology
27.116 Clinical Case: Pulmonary Hypertension
27.117 Clinical Case: Valvular Heart Disease
27.118 Clinical Case: Vascular Medicine
27.119 Clinical Case: Cardiovascular Kidney Metabolic and Prevention
27.120 Clinical Case: Cardio-Obstetrics
27.121 Clinical Case: Surgery
27.122 Clinical Case: Behavioral Medicine
27.123 Clinical Case: Brain Health, Stroke and Neuroscience


COVID-19
No. Category
28.124 Clinical Perspectives


Professional Development
No. Category
29.125 Professional Development, Wellbeing, and Education
(Includes the following: Mentoring Strategies; Innovation in Clinical Education; Teaching/Learning models in Medical Education; Research Career Development, Clinician Psychological Health and Well-Being including burnout.)

Abstract Deadlines

General Abstract Submissions
April 10, 2024 - June 6, 2024 at 7:00 p.m. EST (UTC -4)

Submission Fee:
AHA Professional Member: $45
Non-Member: $95
World Bank Low and Middle Income Countries (PDF): Complimentary

Late-Breaking Science Submissions
June 24, 2024 – August 19, 2024 at 7:00 p.m. EST (UTC -4)

Late-Breaking BASIC Science Submissions
June 24, 2024 – August 19, 2024 at 7:00 p.m. EST (UTC -4)

Presenting at Scientific Sessions differentiates you and can positively impact the trajectory of your scientific career!

Oral Abstract Presentations

  • Engage from the podium with a premier scientific community.
  • Participate in rapid-fire presentations to sharpen how you tell the story of your science.

Moderated Digital Poster & Traditional Posters

  • Converse with senior leaders in your field.
  • Engage with other poster presenters.
  • Expand the reach of your science as all posters are also made available for viewing on the ePoster site
  • Discuss your research with attendees in the Discussion Forum
Scientific Sessions presentations
Presentation Type What it Means
Oral Abstract Presentations
  • 12-min presentation with live Q&A from the audience
  • Q&A opportunity digitally through the Mobile App allows presenters to engage a global audience
  • Publication in Circulation
Rapid-Fire Oral Abstract Presentations
  • 5-min presentation with live Q&A from the audience
  • Q&A opportunity digitally through the Mobile App allows presenters to engage a global audience
  • Publication in Circulation
Moderated Digital Poster Presentations
  • 5-min presentation with live Q&A from the audience
  • An electronic version of your poster available online through the ePoster site
  • Ability to add audio, video or other supporting documents to the ePoster site to support your research
  • Publication in Circulation
Traditional Poster Presentations
  • Specific presentation time for a group of posters with global leaders who are invited to view your poster
  • Engage with the audience as attendees view posters in the poster hall
  • An electronic version of your poster available online through the ePoster site
  • Ability to add audio, video or other supporting documents to the ePoster site to support your research
  • Opportunity to take questions from the global audience via the ePoster tool
  • Publication in Circulation

Overall Abstract Submission Requirements

  • All abstracts must be submitted (and if accepted, will be presented) in English with accurate grammar and spelling suitable for publication.
  • Submit statistical results, including descriptive and inferential statistics.
  • Author must affirm the work submitted is original and all statements declared as facts are based on thorough examination and investigation for accuracy.
  • Authors should not "split" statistical data to create several abstracts from one study. If splitting is judged to have occurred, prior scores of related abstracts will be negatively influenced.
  • Abstracts containing identical or nearly identical data submitted from the same institution and/or people will be disqualified.
  • Proofread abstracts carefully to avoid errors before the submission deadline. The abstract will be published exactly as it has been submitted.
  • Submission of an abstract constitutes a commitment by the author(s) to present if accepted. Failure to present, if not justified, will jeopardize future acceptance of abstracts for American Heart Association meetings/conferences.
  • There is no limit to the number of abstracts an investigator may submit. If selected, the presenter must be one of the co-authors listed. If multiple submissions are accepted, the presenting author must resolve schedule conflicts by arranging for a co-author to present.

Abstract Title

  • An abstract must have a short, specific title (containing no abbreviations or inflammatory language) that indicates the nature of the investigation.
  • Avoid an abstract title that reveals the results of the study. Explicit titles denoting the findings should be used (not "Investigations of … ," "Studies of … ," etc.).

Abstract Text

  • We recommend abstracts have the following identifiable sections:
    • Introduction/Background
    • Research Questions/Hypothesis
    • Goals/Aims
    • Methods/Approach
    • Results/Data (descriptive and inferential statistics)
    • Conclusion(s)
  • Looking for recommendations on how to improve your abstract? We highly recommend you view these recommendations from AHA journals.
  • Use generic drug names.
  • Avoid beginning sentences with numbers.
  • Standard abbreviations may be used without definition. Nonstandard abbreviations (kept to a minimum) must be placed in parentheses after the first use of the word or phrase abbreviated.
  • Do not include references, credits or grant support.
  • Do not include the names or personal informationof anypatient participating in the study or trial.

Abstract Character Guidelines

  • Abstracts are limited to 2,500 characters (about 360-630 words).
  • Counts towards character limit:
    • Spaces in the abstract body
    • Text in the abstract body
    • Graphics: Addition of an image, whether a figure or table, deducts 250 characters.

  • Does not count towards character limit:
    • Title of abstract
    • Names of authors
    • Caption of graphic

Graphics Guidelines

  • All graphics (figures)and text-basedgraphics (tables) shouldbe provided as 72- 300 dpi, pre-sized .BMP, .GIF, .JPG or .PNG images only, with a maximum width of 440 pixels (no limit on length). Black-and-white digital images should be in grayscale mode. Color images should be saved in RGB color mode.
  • All graphics will require a brief description of the image.
  • Please Note: If an abstract is accepted for publication, any images submitted with the abstract are placed after the abstract that will appear in the online only supplement to Circulation, an American Heart Association journal.

Author Name(s)

  • The submitting author will be designated as the primary and presenting author unless otherwise specified. The presenting author must be listed on the abstract and can be listed anywhere in the author block.
  • Please review the author block carefully. Edits cannot be made after the June 6, 7:00 PM EDT/UTC-4 deadline. Once submission is complete, the author block will be published as submitted. Additions or deletions of author names are not permitted after the submission deadline.

Abstract Revisions

  • After the June 6, 2024, 7:00PM EDT/UTC -4 deadline, your abstract submission is considered final and cannot be edited.
    • Abstracts may not be revised in any way or resubmitted.
    • Additions or deletions of author names will not be permitted.
  • Proofread abstracts carefully to avoid errors before submission.

Abstract Copyright Transfer Agreement

  • Abstract Copyright Transfer Agreement will be electronically signed during submission.
    • Your selection of "Yes" will grant permission to publish.
    • Your selection of "No" will prohibit publication of the abstract in all formats including the Circulation supplement, ePoster site, the mobile meeting guide app, abstracts on USB/download and the online program planner.

Abstract Acceptance

  • Abstract acceptance/non-acceptance status will be available by mid-August. Please ensure the email provided for the presenting author is accurate as all correspondence will be sent via email to the presenting author only.
  • All communications regarding your abstract will be sent from [email protected]. Please make sure to add this email address to your email contacts to ensure important program participant-related information gets through your spam filters, etc.
  • All accepted abstracts will be scheduled in oral or poster presentation formats. All presentations including question-and-answers will be conducted in English. Presenters may request assistance from the moderator who will repeat or rephrase questions from the audience or may ask a colleague in the audience to assist with translation.
  • Guidelines for abstract presentation will be included in the acceptance communication.

Abstract Journal Publication

  • Accepted abstracts having selected "Yes" to the Abstract Copyright Transfer Agreement will be published online in the Circulation journal supplement.

Embargo Policy

  • Non-late-breaking abstracts and presentations are embargoed for release at 5:00 AM EST Monday, Nov. 11, 2024, and are therefore prohibited from release until date and time of AHA designated embargo time. You will be contacted by AHA communications if you are selected to participate in an AHA news event.
  • Written embargoed information cannot be shared with anyone outside of the AHA, except for a journal manuscript in which one-on-one embargoed media interviews can be conducted if the reporter agrees to abide by the embargo policy. Failure to honor embargo policies will result in this abstract beingwithdrawnand future abstracts also being barred from presentation. Complete AHA Embargo Policy.

Recording Policy

  • Unauthorized recording of the AHA Scientific Sessions, scientific conferences and the AHA/ASA International Stroke Conference is prohibited, whether by video, still or digital photography, audio or any other recording or reproduction mechanism. This includes recording of presentations and supportingaudiovisual materials and poster presentations and supporting poster materials.
  • The American Heart Association and American Stroke Association reserve the rights to all recordings or reproductions of presentations at AHA/ASA scientific conferences and meetings.

Use of Automated Assistive Writing Technologies and Tools

  • The use of automated assistive writing technologies and tools (commonly referred to as artificial intelligence or machine learning tools) is permitted provided that their use is documented, and authors assume responsibility for the content. As with humangenerated content, authors are responsible for the accuracy, validity and originality of computer-generated content. Automated assistive writing technologies do not qualify for authorship as they are unable to provide approval or consent for submission.
  • If the use of these technologies has involved the research design, the tools should be documented in the Methods sectionof the abstract. For additional information, see the World Association of Medical Editor recommendations.
  • For your abstract submission, you will need to indicate the use of these tools.

Before you submit your general abstract to Scientific Sessions 2024, please use the checklist below to make sure it meets the highlighted submission guidelines and follows best practices.

Text

  • Ensure the title is conclusive, not descriptive. Explicit titles denoting the findings should be used (not "Investigations of… ," "Studies of… ," etc.)
    • Descriptive: "Effects of Hypoxia on Kv1.5 Channels"
    • Conclusive: "Hypoxia Inhibits Kv1.5 Channels in Rat PulmonaryArtery Smooth Muscle Cells"
  • We recommend that abstracts have the following identifiable sections:
    • Introduction/Background
    • Research Questions/Hypothesis
    • Methods/Approach
    • Results/Data (descriptive and inferential statistics)
    • Conclusion(s)
  • Clearly state the hypothesis if you include a hypothesis.
  • Do not include references, credits or grant support information.
  • Minimize the use of abbreviations: Most abstracts should contain fewer than three.
  • Place nonstandard abbreviations in parentheses after the first use of the full word or phrase.
  • Use generic drug names.
  • Do not begin sentences with numbers.
  • Limit text to 2,500 characters for the abstract body.
    • Character count includes graphics, which deducts 250 characters per graphic.
    • Character count does include spaces.
    • Do not include the abstract title or authors in the abstract body.

Graphics

  • Keep graphics simple: Line or bar graphs are most appropriate.
  • Ensure any text is large enough to read when printed.
  • Use only pre-sized .BMP, .GIF, .JPG or .PNG.
  • Save color images in RGB mode.
  • Ensure images are 72-300 dpi.
  • Limit image width to 440 pixels (no limit on length).

NOTE: Proofread abstracts carefully to avoid and/or correct errors before the submission deadline. The abstract will be published exactly as it has been submitted. For full details, see the Submission Guidelines on this page.

When is the General Abstract Submission Deadline?

June 6, 2024, 7:00 PM EST/UTC -4

Are abstract presenters responsible for their expenses associated with participating in Scientific Sessions 2024?

The presenter is responsible for all expenses (e.g., airfare, lodging, conference registration) associated with the submission and presentation of an abstract. The presenting author of an accepted abstract must register for the meeting to present the abstract.

What is the fee for submitting an abstract?

There is a non-refundable submission fee for each abstract submitted.

  • Standard Abstract Fee Pricing:
  • World Bank Abstract Fee Pricing: Complimentary (Please check the LMIC list for your country).

How do I request a refund if I am a member but paid the non-member fee?

  • The last day to request a refund will be 30 days after the submission period closes. Submit a refund request to [email protected].
  • Membership must be active before the submission period ends.
  • Abstract must be submitted using the member’s AHA Professional Heart Daily account to receive the member pricing.
    1. Even if a co-author is a member, member pricing is tied to the account the submitter is signed in with to submit the abstract.

Does AHA Scientific Sessions 2024 accept previously published or presented abstracts?

  • The American Heart Association’s Scientific Sessions 2024 is a forum for the presentation of novel research findings.
  • The work covered by the abstract must not have been presented at a national or international meeting before presentation at Scientific Sessions 2024.
  • Abstracts associated with a published manuscript can be presented at an AHA scientific event if the manuscript was published after the time the abstract was submitted to the event; however, the abstract will not be published as a part of the journal publication.

To what category should I submit my abstract?

To ensure your abstract receives proper scientific consideration, be sure to submit to the appropriate abstract category. Abstract categories can be found on this page.

Can I make edits to my abstract after the submission deadline?

  • After the June 6, 2024, 7:00 PM EST/UTC -4 submission deadline, abstracts are no longer accessible and therefore may not be revised in any way or resubmitted. Additions or deletions of author names will not be permitted.
  • If accepted, your abstract will be published as submitted; it cannot be edited after the submission deadline. Proofread abstracts carefully to avoid errors before the submission deadline.

When will I know if my abstract has been accepted?

  • Abstract acceptance/non-acceptance status will be available by mid-August. Please ensure the email provided for the presenting author is accurate as all correspondences will be sent via email to the presenting author only.
  • All communications regarding your abstract will be sent from [email protected]. Please make sure to add this email address to your email contacts to ensure important program participant-related information gets through your spam filters, etc.

Do you accept Literature Review abstract submissions?

A literature review within the context of a systematic review or meta-analysis research methodology may be considered for acceptance.